Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)

Abstract

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, coronavirus disease 2019 (COVID-19), affecting more than seventeen million people around the world. Diagnosis and treatment guidelines for clinicians caring for patients are needed. In the early stage, we have issued "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)"; now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based guideline. We formed a working group of clinical experts and methodologists. The steering group members proposed 29 questions that are relevant to the

Different characteristics of critical COVID-19 and thinking of treatment strategies in non-elderly and elderly severe adult patients

“…The mechanisms of critical COVID-19 development indicated different responses to anti-inflammatory therapy in non-elderly and elderly severe patients. To date, anti-inflammatory drugs are applied for all patients in addition to anti-viral therapy and general therapy, including interleukin-6 inhibitors, interleukin-1 inhibitors and glucocorticoids [28] . When severe or critical COVID-19 patients’ conditions deteriorate dramatically, low-dose glucocorticoids are recommended by the current guidelines [6] .…”

Molecular mechanism of mureidomycin biosynthesis activated by introduction of an exogenous regulatory gene ssaA into Streptomyces roseosporus

“…The epidemics of Ebola, coronavirus (COVID-19) and other highly pathogenic pathogens have brought severe challenges to the clinical drug application worldwide and call for more effective medicines (Khan et al, 2018;Jin et al, 2020). Genome sequencing and analyses reveal that streptomycetes, as the most important sources of antibiotics for clinical use, have been greatly underestimated for the potential of new drug leads owing to the presence of a large number of unexpressed BGCs for new natural products.…”

Difficulties and Countermeasures in Hospital Emergency Management for Fast-Lane Treatment of Acute Stroke During the COVID-19 Epidemic Prevention and Control

“…Graded protection is carried out according to the position and zone protection standards and material allocation requirements. Department staff are supervised to ensure that they strictly comply with the medical staff protective gear gowning/degowning procedure (56), and suspected medical staff are quarantined and treated in a timely manner. The protection measures for different roles are as follows:…”